ClinicalTrials.gg
CompletedNCT00067938Updated Sep 1, 2016

Bipolar Study in Adults at Least 18 Years of Age

A Phase 4 interventional study of lamotrigine in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 308 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-01.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.

Enrollment
Largest of 33
1,200 · median 72
Started
2003
with 5 others
Phase 4
13 of 33
none open now
Registered
4th of 33
by date
Lead sponsor
9 of 33
GlaxoSmithKline

Among the 33 studies testing lamotrigine in Bipolar Disorder, this one has the largest enrollment, is one of 6 that started in 2003, is one of 13 in phase 4, and was the 4th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About lamotrigine

Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing lamotrigine in Bipolar Disorder as a file.
02

Study summary

Bipolar study of tolerability, clinical response and patient satisfaction

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • bipolar disorder
  • lamotrigine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bipolar I disorder.
  • Must be on a stable regimen of psychiatric medication for at least 2 months prior to study.
  • If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.

Exclusion criteria

Exclusion Criteria:

  • Patients with a psychiatric or physiologic comorbidity including significant substance abuse, depression or mania which is of an unstable of progressive nature that could interfere in participation of this study.
  • Presence of untreated thyroid disease.
  • Patient is actively suicidal or homicidal.
  • Patient has history of severe hepatic or renal insufficiency.
  • Patient is currently participating in another clinical trial.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,200 participants (actual)

Study arms

  • Other
    Arm 1

    Open label single arm study

    Drug: lamotrigine

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint will be the rate of rash during 12 weeks.

    Time frame: 12 Weeks

Secondary outcomes

  1. Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.

    Time frame: 12 Weeks

07

Study locations

308 sites
  • GSK Investigational Site
    Albertville, Alabama 35950, United States
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Birmingham, Alabama 35223, United States
  • GSK Investigational Site
    Birmingham, Alabama 35234, United States
  • GSK Investigational Site
    Fairhope, Alabama 36532, United States
  • GSK Investigational Site
    Huntsville, Alabama 35802, United States
  • GSK Investigational Site
    Tuscaloosa, Alabama 35404, United States
  • GSK Investigational Site
    Chandler, Arizona 85225, United States
  • GSK Investigational Site
    Phoenix, Arizona 85004, United States
  • GSK Investigational Site
    Phoenix, Arizona 85018, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Phoenix, Arizona 85044, United States
  • GSK Investigational Site
    Rogers, Arizona 72756, United States
  • GSK Investigational Site
    Tucson, Arizona 85719, United States
  • GSK Investigational Site
    Fort Smith, Arkansas 72903, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72201, United States
  • GSK Investigational Site
    North Little Rock, Arkansas 72113, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Beverly Hills, California 90210, United States
  • GSK Investigational Site
    Burbank, California 91501, United States
  • GSK Investigational Site
    Campbell, California 95008, United States
  • GSK Investigational Site
    Cerritos, California 90703, United States
  • GSK Investigational Site
    El Centro, California 92243, United States
  • GSK Investigational Site
    Fairfield, California 94533, United States
  • GSK Investigational Site
    La Mesa, California 91941, United States
  • GSK Investigational Site
    Laguna Hills, California 92653, United States
  • GSK Investigational Site
    Los Angeles, California 90011, United States
  • GSK Investigational Site
    Los Angeles, California 90089, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Petaluma, California 94952, United States
  • GSK Investigational Site
    Poway, California 92064, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Diego, California 92114, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Jose, California 95123, United States
  • GSK Investigational Site
    Santa Ana, California 92705, United States
  • GSK Investigational Site
    Santa Barbara, California 93102, United States
  • GSK Investigational Site
    Sherman Oaks, California 91403, United States
  • GSK Investigational Site
    Torrance, California 90505, United States
  • GSK Investigational Site
    West Hollywood, California 90048, United States
  • GSK Investigational Site
    Boulder, Colorado 80303, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80525, United States
  • GSK Investigational Site
    Hamden, Connecticut 06514, United States
  • GSK Investigational Site
    Mansfield Center, Connecticut 06250, United States
  • GSK Investigational Site
    Norwich, Connecticut 06360, United States
  • GSK Investigational Site
    Wethersfield, Connecticut 06109, United States
  • GSK Investigational Site
    Newark, Delaware 19713, United States
  • GSK Investigational Site
    Wilmington, Delaware 19808, United States
  • GSK Investigational Site
    Washington, District of Columbia 20011, United States
  • GSK Investigational Site
    Altamonte Springs, Florida 32714, United States
  • GSK Investigational Site
    Boca Raton, Florida 33432, United States
  • GSK Investigational Site
    Boca Raton, Florida 33433, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33426, United States
  • GSK Investigational Site
    Bradenton, Florida 34209, United States
  • GSK Investigational Site
    Brandon, Florida 33511, United States
  • GSK Investigational Site
    Casselberry, Florida 32730, United States
  • GSK Investigational Site
    Clearwater, Florida 33764, United States
  • GSK Investigational Site
    Coral Springs, Florida 33065, United States
  • GSK Investigational Site
    Davie, Florida 33024, United States
  • GSK Investigational Site
    Daytona Beach, Florida 32114, United States
  • GSK Investigational Site
    Destin, Florida 32541, United States
  • GSK Investigational Site
    Fort Walton Beach, Florida 32548, United States
  • GSK Investigational Site
    Gainesville, Florida 32607, United States
  • GSK Investigational Site
    Jacksonville Beach, Florida 32250, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Jacksonville, Florida 32257, United States
  • GSK Investigational Site
    Lakeland, Florida 33803, United States
  • GSK Investigational Site
    Miami, Florida 32216, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33157, United States
  • GSK Investigational Site
    Miami, Florida 33176, United States
  • GSK Investigational Site
    North Miami, Florida 33161, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Ocala, Florida 34474, United States
  • GSK Investigational Site
    Orange City, Florida 32763, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Palm Beach Gardens, Florida 33410, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    Plantation, Florida 33324, United States
  • GSK Investigational Site
    Sarasota, Florida 34238, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33701, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33702, United States
  • GSK Investigational Site
    Syracuse, Florida 13202, United States
  • GSK Investigational Site
    Tampa, Florida 33603, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Wilton Manors, Florida 33311, United States
  • GSK Investigational Site
    Winter Park, Florida 32789, United States
  • GSK Investigational Site
    Winter Park, Florida 32792, United States
  • GSK Investigational Site
    Zephyrhills, Florida 33540, United States
  • GSK Investigational Site
    Atlanta, Georgia 30030, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309-7520, United States
  • GSK Investigational Site
    Atlanta, Georgia 30338, United States
  • GSK Investigational Site
    Decatur, Georgia 30030, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Roswell, Georgia 30075, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States

Showing the first 100 of 308 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Aug 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2003
First posted
Sep 5, 2003
Start
Aug 2003
Primary completionActual
Aug 2004
CompletionActual
Aug 2004
Last update
Sep 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00067938
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 5, 2003
Start date
Aug 2003
Primary completion
Aug 2004
Completion
Aug 2004
Last update
Sep 1, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion